Quality of Life Study With Adalimumab in Rheumatoid Arthritis

Last updated: October 2, 2007
Sponsor: Abbott
Overall Status: Completed

Phase

3

Condition

Rheumatoid Arthritis

Joint Injuries

Dermatomyositis (Connective Tissue Disease)

Treatment

N/A

Clinical Study ID

NCT00234936
MEXI -P01-03
ESCALAR
  • Ages > 18
  • All Genders

Study Summary

The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject is age 18 or older and in good health (Investigator discretion) with a recentstable medical history

  • Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria

  • Subjects with treatment failure criteria to Mtx or Mtx + another DMARD

Exclusion

Exclusion Criteria:

  • Subject considered by the investigator, for any reason, to be an unsuitable candidatefor the study

  • Female subject who is pregnant or breast-feeding or considering becoming pregnant

  • Previous treatment with approved biological agents (etanercept, infliximab, anakinra)in the last 2 months

Study Design

Total Participants: 200
Study Start date:
December 01, 2003
Estimated Completion Date: